This M2 differentiation was prevented by treatment with tocilizumab, suggesting that this antibody might increase the clinical effect of platinum-based chemotherapy.[33] However, in our study, all samples of primary cells from ovarian cancer ascites were collected before chemotherapies and it appears that the enriched IL-6 accumulation in ascites is seen at advanced stages regardless of chemotherapies. This evidence concerns the gene IL6 and ovarian carcinoma.